SubHero Banner

Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – New drug approval

February 7, 2018 - Gilead announced the FDA approval of Biktarvy (bictegravir [BIC]/emtricitabine [FTC]/tenofovir alafenamide [TAF]), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

Download PDF